Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 3/20 | 0.54 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.54 |
| ▸ | IKZF2 | Q9UKS7 | 14/20 | 0.42 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25036615 | 0.91 | DDB1 (0.58) | DDB1CRBNIKZF2 | |
| SCHEMBL25036590 | 0.91 | DDB1 (0.58) | DDB1CRBNIKZF2 | |
| SCHEMBL30273456 | 0.91 | DDB1 (0.58) | DDB1CRBNIKZF2 | |
| SCHEMBL22526963 | 0.90 | DDB1 (0.55) | DDB1CRBNIKZF2IKZF1DRD2 | |
| SCHEMBL23540460 | 0.90 | DDB1 (0.56) | DDB1CRBNIKZF2IKZF1 | |
| SCHEMBL23540165 | 0.90 | DDB1 (0.56) | DDB1CRBNIKZF2IKZF1 | |
| SCHEMBL23540806 | 0.90 | DDB1 (0.56) | DDB1CRBNIKZF2IKZF1 | |
| Hydrochloric Acid SCHEMBL30258255 | 0.89 | DDB1 (0.56) | DDB1CRBNIKZF2IKZF1 | |
| SCHEMBL30289187 | 0.89 | DDB1 (0.57) | DDB1CRBNIKZF2IKZF1DRD2 | |
| SCHEMBL22526962 | 0.88 | DDB1 (0.53) | DDB1CRBNIKZF2IKZF1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |